Chemical structure of molecule compound 17a

SGK1 kinase inhibitor

preclinical activity in osteoarthritis explant model

from DFG-out virtual screening, SBDD and MPO

Journal of Medicinal Chemistry

Sanofi, Frankfurt am Main, DE

Kinase inhibitors are increasingly being explored for diseases beyond cancer. While SGK1 has been a cancer target, SGK1 has also been implicated in osteoarthritis pathology, and the Sanofi team…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.